Source: [People's Daily Health Client] Vaccine News The first clinical shot of the first inactivated Omickron vaccine was launched on May 2, China Biologics announced that the clinical study of the inactivated Omickron variant strain of the new coronavirus developed by Sinopharm

2025/04/2419:27:35 hotcomm 1679

Source: [People's Daily Health Client]

Vaccine News

First clinical shot of inactivated vaccine for the first Omickron strain inactivated vaccine for the first clinical shot of the first Omickron strain inactivated vaccine developed by Sinopharm Group China Biologics Beijing Institute of Biological Products, and completed the first dose of vaccination in Hangzhou, Zhejiang Province. This is the world's first inactivated coronavirus vaccine against the Omickron variant that has entered clinical trials. (People's Daily Health Client)

Source: [People's Daily Health Client] Vaccine News The first clinical shot of the first inactivated Omickron vaccine was launched on May 2, China Biologics announced that the clinical study of the inactivated Omickron variant strain of the new coronavirus developed by Sinopharm  - DayDayNews

China Biologics official WeChat official account map

R&D dynamic

Ruike Biologics: The new crown vaccine is approved for clinical trials

Jiangsu Ruike Biotechnology Co., Ltd. announced on May 2 that the company has recently obtained clinical trial approval from the State Administration of Drug Administration of the People's Republic of China for its recombinant protein COVID-19 vaccine ReCOV. ReCOV is the next generation recombinant protein vaccine developed by Reco Bio in a comprehensive manner using new adjuvants, protein engineering platforms and other technical platforms. It has good cross-neutralization and immune durability for mutant viruses such as Omickron and Delta. (People's Daily Health Client)

Zhifei Bio: Phase III results of the new crown recombinant protein vaccine published

On May 4, the New England Journal published the effectiveness and safety data of Anhui Zhifei Longcoma Bio's recombinant novel coronavirus protein vaccine (CHO cells) (ZF2001) in preventing new crown infection in adults. In the latest analysis, 158 of 12,625 subjects in the ZF2001 group and 580 of 12,568 subjects in the placebo group reported primary endpoint cases, with a vaccine effectiveness of 75.7% (95% confidence interval [CI], 71.0-79.8). (Official WeChat official account)

Clover Bio: Bivalent vaccine candidate has a neutralizing effect on Omickron

Clover Bio issued an announcement on the Hong Kong Stock Exchange on the evening of May 5, announcing positive new data on preclinical research of the bivalent COVID-19 vaccine candidate. The data showed that it had an effective neutralizing effect on all variants worthy of attention, including the Omickron variant.

Source: [People's Daily Health Client] Vaccine News The first clinical shot of the first inactivated Omickron vaccine was launched on May 2, China Biologics announced that the clinical study of the inactivated Omickron variant strain of the new coronavirus developed by Sinopharm  - DayDayNews

Clover Biological Official Website Picture

CanSino Biologics: Launched Phase I clinical trial of the new crown mRNA vaccine

May 5, according to the Insight database, CanSino Biologics registered to launch Phase I clinical trial of the new crown mRNA vaccine, mainly targeting adults aged 18 and above. It is understood that on April 4, the new coronavirus mRNA vaccine developed by CanSino Biologics has obtained the approval document for drug clinical trials of the State Food and Drug Administration.

(Vaccine Channel Submission, Industry Exchange Email [email protected])

Editor: Zhu Xiaona Proofreader: Lu Yang

This article comes from [People's Daily Health Client] and only represents the author's views. The national party media information public platform provides information release and dissemination services.

ID: jrtt

hotcomm Category Latest News